The systemic Ben Brik score, MAROC 22: A mechanism-anchored bedside instrument for the surveillance of reversible cognitive burden in octogenarians—A single-center pilot

BackgroundCognitive decline in octogenarians is routinely attributed to irreversible neurodegeneration, yet a substantial fraction is driven by partly reversible physiological mechanisms. Oxidative and mitochondrial damage are among the earliest events in Alzheimer's disease pathology, upstream of amyloid deposition, and this framework has not been operationalized into a bedside instrument for the oldest-old.ObjectiveTo present the SBG-MAROC 22-a 310-point, 22-parameter, seven-pillar bedside matrix whose item weights are anchored to published hazard ratios for incident dementia-and to report preliminary single-center data on its feasibility and capacity to flag reversible contributors and acute decompensation.MethodsSingle-center, single-author, retrospective pilot. Forty-seven consecutive patients aged ≥ 80 years [mean age 83.7 ± 2.9 years; 55.3% female; baseline Montreal Cognitive Assessment (MoCA) 16.2 ± 4.1] were assessed with the SBG-MAROC 22 alongside the MoCA. A subgroup (n = 11) received the PD-GOLD protocol with MoCA reassessment at ∼45 days. No power calculation or concurrent control group; reporting followed STROBE.ResultsThe score showed a preliminary association with concurrent MoCA (r≈0.78), within-pilot inter-rater agreement (κ≈0.85), and at least one reversible contributor in 89.4% of patients. The treated subgroup gained a mean +6.0 MoCA points at 45 days (95% CI +3.0 to +9.0; prediction interval -3.1 to +15.1, crossing zero). An exploratory FXTAS-versus-Alzheimer's area under the curve was 0.92. All values are internal, uncontrolled pilot estimates, not validation.ConclusionsThe SBG-MAROC 22 is a clinically feasible, MRI-independent bedside instrument whose hypothesis-generating profile warrants independent, blinded, prospective multicenter validation before any clinical use. Claims of validated discrimination or therapeutic efficacy are not made.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-08-03
DOI
https://doi.org/10.1177/13872877261474889
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The systemic Ben Brik score, MAROC 22: A mechanism-anchored bedside instrument for the surveillance of reversible cognitive burden in octogenarians—A single-center pilot

Soufiane Ben Brik
Journal of Alzheimer s Disease
Dementia and Cognitive Impairment Research
article

The systemic Ben Brik score, MAROC 22: A mechanism-anchored bedside instrument for the surveillance of reversible cognitive burden in octogenarians—A single-center pilot

Soufiane Ben Brik
article en

Abstract

BackgroundCognitive decline in octogenarians is routinely attributed to irreversible neurodegeneration, yet a substantial fraction is driven by partly reversible physiological mechanisms. Oxidative and mitochondrial damage are among the earliest events in Alzheimer's disease pathology, upstream of amyloid deposition, and this framework has not been operationalized into a bedside instrument for the oldest-old.ObjectiveTo present the SBG-MAROC 22-a 310-point, 22-parameter, seven-pillar bedside matrix whose item weights are anchored to published hazard ratios for incident dementia-and to report preliminary single-center data on its feasibility and capacity to flag reversible contributors and acute decompensation.MethodsSingle-center, single-author, retrospective pilot. Forty-seven consecutive patients aged ≥ 80 years [mean age 83.7 ± 2.9 years; 55.3% female; baseline Montreal Cognitive Assessment (MoCA) 16.2 ± 4.1] were assessed with the SBG-MAROC 22 alongside the MoCA. A subgroup (n = 11) received the PD-GOLD protocol with MoCA reassessment at ∼45 days. No power calculation or concurrent control group; reporting followed STROBE.ResultsThe score showed a preliminary association with concurrent MoCA (r≈0.78), within-pilot inter-rater agreement (κ≈0.85), and at least one reversible contributor in 89.4% of patients. The treated subgroup gained a mean +6.0 MoCA points at 45 days (95% CI +3.0 to +9.0; prediction interval -3.1 to +15.1, crossing zero). An exploratory FXTAS-versus-Alzheimer's area under the curve was 0.92. All values are internal, uncontrolled pilot estimates, not validation.ConclusionsThe SBG-MAROC 22 is a clinically feasible, MRI-independent bedside instrument whose hypothesis-generating profile warrants independent, blinded, prospective multicenter validation before any clinical use. Claims of validated discrimination or therapeutic efficacy are not made.

Journal of Alzheimer s Disease
Instituts Supérieurs des Professions Infirmières et Techniques de Santé (MA)
Gender equality
Openalex Percentile: Top 9%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.